News Medical on MSN2 天
New Alzheimer's Strategy for Amyloid Diagnostics
A research group at LMU University Hospital has investigated how Alzheimer's disease can be diagnosed more reliably in the ...
The Pharma Letter11 小时
Alector AL002 INVOKE-2 Phase II Alzheimer’s trial misses goal
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...
AlphaGalileo2 天
Alzheimer’s: new strategy for amyloid diagnostics
A research group at LMU University Hospital has investigated how Alzheimer’s disease can be diagnosed more reliably in the future.
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off ...
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early ...
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
Centiloid guidelines and recommendations released for clinical context-of-use in Alzheimer ...
The members of the Amyloid imaging to prevent Alzheimer's disease (AMYPAD) have announced the publication of a perspective ...
ALZFORUM7 天
Biomarkers Suggest Black and Hispanic People Less Likely to Have Amyloid
New screening data reported from ongoing and past trials indicated that, across racial and ethnic groups, blood biomarkers were faithful predictors of amyloid plaques lurking in the brain. However, in ...
GlobalData on MSN1 天
Alector stock drops after Alzheimer’s drug fails in Phase II trial
"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...